PGR and breast carcinoma: ERα‐36 has also been identified as a regulator of progesterone receptor (PR) activity in breast cancer, exerting control over both signaling and transcriptional processes associated with progesterone, resulting in increased cell proliferation and migration (Fig. 4) [38].